MiNK Therapeutics Aktie

MiNK Therapeutics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3C5HZ / ISIN: US6036931029

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
14.08.2025 20:45:47

MiNK Therapeutics Extends Cash Runway

MiNK Therapeutics(NASDAQ:INKT) reported its fiscal second quarter ended June 30, 2025, on Aug. 14, 2025, posting a $4.2 million net loss and announcing a $13 million equity raise after quarter-end, which extends its cash runway through mid-2026. Key milestones included a published complete remission case with AGENT-797 in metastatic testicular cancer, a year-over-year operating cash burn reduction of over 30%, and new external non-dilutive funding for upcoming clinical trials. The following analysis highlights three major developments with direct implications for long-term investors.Following a peer-reviewed publication, the company’s market capitalization increased, drawing renewed interest from both investors and potential partners. Management confirmed that late-stage partnership discussions are ongoing, with a focus on maximizing value across scientific and operational assets while leveraging capital-efficient structures.If a partnership is secured on favorable terms, investors could benefit from non-dilutive capital and an extended cash runway, supporting further development of the INKT cell therapy platform.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Nachrichten zu MiNK Therapeutics Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu MiNK Therapeutics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!